Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-18
2005-01-18
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S230000, C544S254000
Reexamination Certificate
active
06844348
ABSTRACT:
The invention provides a compound of formula (I):wherein R1is alkyl C1-6or alkenyl C2-6, both independently optionally substituted by one or more groups selected from alkyl C1-5or halogen; R2is cycloalkyl C3-8, optionally substituted by R3; R3is phenyl, optionally substituted by one or more groups selected from alkyl C1-6or halogen; R4and R5are alkyl C1-6or together cycloalkyl C3-6. These compounds are useful for the treatment of stable and unstable angina.
REFERENCES:
patent: WO-9905143 (1999-02-01), None
West, Anthony R., “Solid State Chemistry and its Applications”, Wiley, New York, 1988, pp. 358 & 365.*
Patricia Cluttona, John D. Foltsb and Jane E. Freedmana, Pharamcological Research, vol. 44, Issue 4, Oct. 2001, pp. 255-264.*
Storey, R.F. et al, Thromb. Haemost., 2001, 85(3), pp. 401-407, Medline Abstract PMID 11307804.
Guile Simon
Martin Barrie
AstraZeneca AB
McKenzie Thomas C.
Ropes & Gray LLP
LandOfFree
2,3,4-cyclopentan-2,3,4-triol-1-yl compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2,3,4-cyclopentan-2,3,4-triol-1-yl compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2,3,4-cyclopentan-2,3,4-triol-1-yl compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3371245